

## DAFTAR PUSTAKA

- Anshu Gupta, T. D. (2017) 'A Simplified Overview of WHO Classification Update', *Neuroscience*, 8(1), p. 4103. doi: 10.4103/jnnp.jnnp.
- Araki, Y. *et al.* (2011) 'Quantitative digital assessment of MGMT immunohistochemical expression in glioblastoma tissue', *Brain Tumor Pathology*, 28(1), pp. 25–31. doi: 10.1007/s10014-010-0004-2.
- Ardhini, R. and Tugasworo, D. (2019) 'Epidemiology of primary brain tumors in dr. Kariadi Hospital Semarang in 2015-2018', *E3S Web of Conferences*, 125(2019), pp. 1–8. doi: 10.1051/e3sconf/201912516004.
- Barciszewska, A. M. *et al.* (2015) 'A new epigenetic mechanism of temozolomide action in glioma cells', *PLoS ONE*, 10(8). doi: 10.1371/journal.pone.0136669.
- Barnholtz-Sloan, J. S., Ostrom, Q. T. and Cote, D. (2018) 'Epidemiology of Brain Tumors', *Neurologic Clinics*. Elsevier Inc, 36(3), pp. 395–419. doi: 10.1016/j.ncl.2018.04.001.
- Bell, E. H. *et al.* (2018) 'Association of MGMT Promoter Methylation Status with Survival Outcomes in Patients with High-Risk Glioma Treated with Radiotherapy and Temozolomide: An Analysis from the NRG Oncology/RTOG 0424 Trial', *JAMA Oncology*, 4(10), pp. 1405–1409. doi: 10.1001/jamaoncol.2018.1977.
- Bohn, A. *et al.* (2018) 'The association between race and survival in glioblastoma patients in the US: A retrospective cohort study', *PLoS ONE*, 13(6), pp. 1–10. doi: 10.1371/journal.pone.0198581.
- Brandes, A. A. *et al.* (2010) 'O6-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: Clinical implications', *Neuro-Oncology*, 12(3), pp. 283–288. doi: 10.1093/neuonc/nop050.
- Brell, M. *et al.* (2005) 'Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas', *Clinical Cancer Research*, 11(14), pp. 5167–5174. doi: 10.1158/1078-0432.CCR-05-0230.
- Brell, M., Ibáñez, J. and Tortosa, A. (2011) 'O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: Systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction', *BMC Cancer*, 11, pp. 5–7. doi: 10.1186/1471-2407-11-35.

- Buckner, J. C. *et al.* (2001) 'The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents [1] (multiple letters)', *New England Journal of Medicine*, 344(9), pp. 686–688. doi: 10.1056/NEJM200103013440914.
- Cankovic, M. *et al.* (2007) 'A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue', *Laboratory Investigation*, 87(4), pp. 392–397. doi: 10.1038/labinvest.3700520.
- Capper, D. *et al.* (2008) 'Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: Proposal of a feasible immunohistochemical approach', *Acta Neuropathologica*, 115(2), pp. 249–259. doi: 10.1007/s00401-007-0310-x.
- Christmann, M. *et al.* (2011) 'O6-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: Enzyme activity, promoter methylation and immunohistochemistry', *Biochimica et Biophysica Acta - Reviews on Cancer*. Elsevier B.V., 1816(2), pp. 179–190. doi: 10.1016/j.bbcan.2011.06.002.
- Clark, O., Yen, K. and Mellinghoff, I. K. (2016) 'Molecular pathways: Isocitrate dehydrogenase mutations in cancer', *Clinical Cancer Research*, 22(8), pp. 1837–1842. doi: 10.1158/1078-0432.CCR-13-1333.
- Cohen, A. (2013) 'IDH1 and IDH2 Mutations in Gliomas', *Current Neurology and Neuroscience Reports*, 13(5), p. 345. doi: 10.1038/jid.2014.371.
- Dang, L., Yen, K. and Attar, E. C. (2016) 'IDH mutations in cancer and progress toward development of targeted therapeutics', *Annals of Oncology*, 27(4), pp. 599–608. doi: 10.1093/annonc/mdw013.
- Ducray, F. *et al.* (2011) 'Predictive and prognostic factors for gliomas', *Expert Review of Anticancer Therapy*, 11(5), pp. 781–789. doi: 10.1586/era.10.202.
- Fatchiyah et al (2011) *Biologi Molekuler*. Edited by R. Astikawati. Erlangga.
- Feldheim, J. *et al.* (2019) 'Changes of o6-methylguanine dna methyltransferase (Mgmt) promoter methylation in glioblastoma relapse—a meta-analysis type literature review', *Cancers*, 11(12). doi: 10.3390/cancers11121837.
- Gattuso Paolo et all (2015) *DIFFERENTIAL DIAGNOSIS IN SURGICAL PATHOLOGY, THIRD EDITION*. 3 ed. Edited by D. J. S. M. H. H. . O. D. P. G. V. B. Reddy. Elsevier.
- Groenendijk, F. H. *et al.* (2011) 'MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation', *Journal of Neuro-Oncology*, 101(3), pp. 405–417. doi: 10.1007/s11060-010-0274-x.

- Hamdani, Chairil; Ham, MF;Siregar, N. (2012) *No Title*. Jakarta: FK UI.
- Hanif, F. *et al.* (2017) ‘Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment’, *Asian Pacific Journal of Cancer Prevention*, 18(1), pp. 3–9. doi: 10.22034/APJCP.2017.18.1.3.
- Håvik, A. B. *et al.* (2012) ‘MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR’, *Journal of Translational Medicine*, 10(1), pp. 1–13. doi: 10.1186/1479-5876-10-36.
- Hegi, M. E. *et al.* (2005) ‘MGMT gene silencing and benefit from temozolomide in glioblastoma’, *New England Journal of Medicine*, 352(10), pp. 997–1003. doi: 10.1056/NEJMoa043331.
- Horbinski, C. (2010) ‘Practical molecular diagnostics in neuropathology: Making a tough job a little easier’, *Seminars in Diagnostic Pathology*, 27(2), pp. 105–113. doi: 10.1053/j.sem dp.2010.04.001.
- Hsu, C. Y. *et al.* (2017) ‘Comparative Assessment of 4 Methods to Analyze MGMT Status in a Series of 121 Glioblastoma Patients’, *Applied Immunohistochemistry and Molecular Morphology*, 25(7), pp. 497–504. doi: 10.1097/PAI.0000000000000331.
- International Agency for Research on Cancer (IARC) (2020) ‘Indonesia - Global Cancer Observatory’, *Globocan*, 858, pp. 1–2.
- Jacinto, F. V. and Esteller, M. (2007) ‘MGMT hypermethylation: A prognostic foe, a predictive friend’, *DNA Repair*, 6(8), pp. 1155–1160. doi: 10.1016/j.dnarep.2007.03.013.
- Kristensen, L. S. *et al.* (2016) ‘Assessment of quantitative and allelic MGMT methylation patterns as a prognostic marker in glioblastoma’, *Journal of Neuropathology and Experimental Neurology*, 75(3), pp. 246–255. doi: 10.1093/jnen/nlv024.
- Li, Q. *et al.* (2017) ‘Relationship between MGMT gene expression and treatment effectiveness and prognosis in glioma’, *Oncology Letters*, 14(1), pp. 229–233. doi: 10.3892/ol.2017.6123.
- Lipp, E. S. *et al.* (2019) ‘MGMT: Immunohistochemical detection in high-grade astrocytomas’, *Journal of Neuropathology and Experimental Neurology*, 78(1), pp. 57–64. doi: 10.1093/jnen/nly110.
- Louis, D. N. *et al.* (2016) ‘The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary’, *Acta Neuropathologica*. Springer Berlin Heidelberg, 131(6), pp. 803–820. doi: 10.1007/s00401-016-1545-1.

- Louis et al (2016) *WHO classification of tumours of the central nervous system: WHO Classification of Tumours v. 1 (World Health Organization classification of tumours)*. Revised 4t. Edited by David N. Louis; Hiroko Ohgaki; Otmar D. Wiestier; Webster K. Cavenee; David W. Ellison; Dominique Figarella-Branger; Arie Perry; Guido Reifenberger; Andreas von Deimling. Heidelberg: International Agency for Research on Cancer (IARC) 69372 Lyon Cedex 08, France. Available at: <http://www.amazon.co.uk/classification-tumours-central-nervous-system/dp/9283224302>.
- Mansouri, A. *et al.* (2019) ‘MGMT promoter methylation status testing to guide therapy for glioblastoma: Refining the approach based on emerging evidence and current challenges’, *Neuro-Oncology*, 21(2), pp. 167–178. doi: 10.1093/neuonc/noy132.
- Manuel, J.-M. *et al.* (2016) ‘Role of Concurrent Methylation Pattern of MGMT, TP53 and CDKN2A Genes in the Prognosis of High Grade Glioma’, *Journal of Carcinogenesis & Mutagenesis*, 07(01), pp. 1–8. doi: 10.4172/2157-2518.1000250.
- Mason, S. and McDonald, K. (2012) ‘MGMT testing for glioma in clinical laboratories: Discordance with methylation analyses prevents the implementation of routine immunohistochemistry’, *Journal of Cancer Research and Clinical Oncology*, 138(11), pp. 1789–1797. doi: 10.1007/s00432-012-1312-1.
- McCormack, A. *et al.* (2013) ‘MGMT expression and pituitary tumours: Relationship to tumour biology’, *Pituitary*, 16(2), pp. 208–219. doi: 10.1007/s11102-012-0406-8.
- Mellai, M. *et al.* (2012) ‘MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors’, *Journal of Neuro-Oncology*, 107(3), pp. 617–631. doi: 10.1007/s11060-011-0787-y.
- Molenaar, R. J. *et al.* (2014) ‘The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone’, *Neuro-Oncology*, 16(9), pp. 1263–1273. doi: 10.1093/neuonc/nou005.
- Mondesir, J. *et al.* (2016) ‘IDH1 and IDH2 mutations as novel therapeutic targets: Current perspectives’, *Journal of Blood Medicine*, 7, pp. 171–180. doi: 10.2147/JBM.S70716.
- Mukasa, A. *et al.* (2012) ‘Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients’, *Cancer Science*, 103(3), pp. 587–592. doi: 10.1111/j.1349-7006.2011.02175.x.
- Pan, Q. *et al.* (2016) ‘Heterogeneity of MGMT gene promoter methylation and protein expression in serial specimens in newly diagnosed glioblastoma’,

*International Journal of Clinical and Experimental Medicine*, 9(9), pp. 17356–17366.

- Pandith, A. A. *et al.* (2018) ‘Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide)’, *Scientific Reports*. Springer US, 8(1), pp. 1–11. doi: 10.1038/s41598-018-25169-2.
- Pandith, A. A. *et al.* (2021) ‘Favorable role of IDH 1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma’, *Future Science OA*, 7(3), p. FSO663. doi: 10.2144/fsoa-2020-0057.
- Park, J. W. and Turcan, Ş. (2019) ‘Epigenetic reprogramming for targeting IDH-mutant malignant gliomas’, *Cancers*, 11(10), pp. 1–17. doi: 10.3390/cancers11101616.
- Parkinson, J. F. *et al.* (2008) ‘Variation of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma’, *Journal of Neuro-Oncology*, 87(1), pp. 71–78. doi: 10.1007/s11060-007-9486-0.
- Parrella, P. *et al.* (2009) ‘High specificity of quantitative methylation-specific pcr analysis for mgmt promoter hypermethylation detection in gliomas’, *Journal of Biomedicine and Biotechnology*, 2009. doi: 10.1155/2009/531692.
- Perry, A. and Brat, D. (2010) *Practical Surgical Neuropathology: A Diagnostic Approach*, *Practical Surgical Neuropathology: A Diagnostic Approach*. Edited by D. J. B. Arie Perry. Elsevier. doi: 10.1016/C2009-0-35968-1.
- Pfeifer, G. P. (2018) ‘Defining driver DNA methylation changes in human cancer’, *International Journal of Molecular Sciences*, 19(4), pp. 1–13. doi: 10.3390/ijms19041166.
- Pinson, H. *et al.* (2020) ‘Weak MGMT gene promoter methylation confers a clinically significant survival benefit in patients with newly diagnosed glioblastoma: a retrospective cohort study’, *Journal of Neuro-Oncology*. Springer US, 146(1), pp. 55–62. doi: 10.1007/s11060-019-03334-5.
- Quillien, V. *et al.* (2012) ‘Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA- methyltransferase in a series of 100’, *Cancer*, 118(17), pp. 4201–4211. doi: 10.1002/cncr.27392.
- Reifenberger, G. *et al.* (2012) ‘Predictive impact of MGMT promoter methylation in glioblastoma of the elderly’, *International Journal of Cancer*, 131(6), pp. 1342–1350. doi: 10.1002/ijc.27385.



- Reifenberger, G. *et al.* (2017) 'Advances in the molecular genetics of gliomas-implications for classification and therapy', *Nature Reviews Clinical Oncology*. Nature Publishing Group, 14(7), pp. 434–452. doi: 10.1038/nrclinonc.2016.204.
- Riemenschneider, M. J. *et al.* (2010) 'Molecular diagnostics of gliomas: State of the art', *Acta Neuropathologica*, 120(5), pp. 567–584. doi: 10.1007/s00401-010-0736-4.
- Rivera, Andreana L. *et al.* (2010) 'MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma', *Neuro-Oncology*, 12(2), pp. 116–121. doi: 10.1093/neuonc/nop020.
- Rivera, Andreana L *et al.* (2010) 'N E U R O - O N C O L O G Y chemotherapy for glioblastoma', 12(2), pp. 116–121.
- Rosas-Alonso, R. *et al.* (2020) 'Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients', *Clinical Epigenetics*. BioMed Central, pp. 1–13. doi: 10.1186/s13148-021-01044-2.
- Shamsara, J. *et al.* (2009) 'Association between MGMT promoter hypermethylation and p53 mutation in glioblastoma', *Cancer Investigation*, 27(8), pp. 825–829. doi: 10.1080/07357900902783211.
- Sharma, S. *et al.* (2009) 'Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis', *Anticancer Research*, 29(10), pp. 3759–3768.
- Siegel, R. L., Miller, K. D. and Jemal, A. (2020) 'Cancer statistics, 2020', CA: A *Cancer Journal for Clinicians*, 70(1), pp. 7–30. doi: 10.3322/caac.21590.
- Spiegel-Kreinecker, S. *et al.* (2010) 'O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients', *Neuro-Oncology*, 12(1), pp. 28–36. doi: 10.1093/neuonc/nop003.
- Sze, C. I. *et al.* (2013) 'Assessing current therapeutic approaches to decode potential resistance mechanisms in glioblastomas', *Frontiers in Oncology*, 3 MAR(March), pp. 1–7. doi: 10.3389/fonc.2013.00059.
- Thon, N., Kreth, S. and Kreth, F. W. (2013) 'Personalized treatment strategies in glioblastoma: MGMT promoter methylation status', *OncoTargets and Therapy*, 6, pp. 1363–1372. doi: 10.2147/OTT.S50208.
- Uno, M. *et al.* (2011) 'Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma', *Clinics*, 66(10), pp. 1747–1755. doi: 10.1590/S1807-59322011001000013.

- Vogel, H. (2009) *Nervous system: Cambridge illustrated surgical pathology, Nervous System: Cambridge Illustrated Surgical Pathology*. doi: 10.1017/CBO9780511581076.
- Wang, L. *et al.* (2017) ‘Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas’, *Pathology Research and Practice*. Elsevier, 213(12), pp. 1489–1493. doi: 10.1016/j.prp.2017.10.007.
- Weller, M. *et al.* (2010) ‘MGMT promoter methylation in malignant gliomas: Ready for personalized medicine?’, *Nature Reviews Neurology*. Nature Publishing Group, 6(1), pp. 39–51. doi: 10.1038/nrneurol.2009.197.
- Wesseling, P. and Capper, D. (2018) ‘WHO 2016 Classification of gliomas’, *Neuropathology and Applied Neurobiology*, 44(2), pp. 139–150. doi: 10.1111/nan.12432.
- Yan, H. *et al.* (2009) ‘Mutations in Gliomas’, *New England Journal of Medicine*, 360(8), pp. 765–773.
- Younis, S. G., Khedr, R. A. E. G. and El-Shorbagy, S. H. (2016) ‘Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide’, *Journal of the Egyptian National Cancer Institute*. National Cancer Institute, Cairo University, 28(1), pp. 23–30. doi: 10.1016/j.jnci.2015.11.003.